Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

Robin Jean Bell; Pam Fradkin; Max Allan Schwarz; Susan Ruth Davis

doi:10.1097/gme.0b013e3182610cab

Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

Robin Jean Bell, Pam Fradkin, Max Allan Schwarz, Susan Ruth Davis

Research output: Contribution to journal › Article › Research › peer-review

17 Citations (Scopus)

Abstract

Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation

Original language	English
Pages (from-to)	15 - 21
Number of pages	7
Journal	Menopause
Volume	20
Issue number	1
DOIs	https://doi.org/10.1097/gme.0b013e3182610cab
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/gme.0b013e3182610cab

Cite this

@article{facee2673ed745f091dedfc64081a27b,

title = "Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis",

abstract = "Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation",

author = "Bell, {Robin Jean} and Pam Fradkin and Schwarz, {Max Allan} and Davis, {Susan Ruth}",

year = "2013",

doi = "10.1097/gme.0b013e3182610cab",

language = "English",

volume = "20",

pages = "15 -- 21",

journal = "Menopause",

issn = "1072-3714",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

AU - Bell, Robin Jean

AU - Fradkin, Pam

AU - Schwarz, Max Allan

AU - Davis, Susan Ruth

PY - 2013

Y1 - 2013

N2 - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation

AB - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation

UR - http://www.ncbi.nlm.nih.gov/pubmed/22948136

U2 - 10.1097/gme.0b013e3182610cab

DO - 10.1097/gme.0b013e3182610cab

M3 - Article

VL - 20

SP - 15

EP - 21

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -

Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

Abstract

UN SDGs

Access to Document

Other files and links

Cite this